Suven Life Sciences has received a patent each by Israel and Mexico for a drugused for treating neuro degenerative diseases.
Suven Life has said in a BSE filing that it has been granted “one product patent from Israel and one product patent from Mexico corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenrative diseases”.
It further said that the patents are valid till 2032.
Suven has said that “These granted patents are exclusive intellectual property of Suven and are achieved through internal discoveryresearch efforts. Products out of these inventions may be out-licensed at various phases of clinical development likephase-I or phase-II.”
